Indacaterol EfectIveness In COPD Patients With Tuberculosis History
NCT01778062
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
136
Enrollment
INDUSTRY
Sponsor class
Conditions
Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
Interventions
DRUG:
Indacaterol
DRUG:
Control
Sponsor
Novartis Pharmaceuticals